Paper35547769
Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
Lu L and 12 others. Theranostics, 2022. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Papers, record 35547769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35547769
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| B7-H1 Antigen | Major topic |
| Colorectal Neoplasms | Major topic |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Immune Checkpoint Inhibitors | |
| Immunologic Factors | |
| Immunotherapy | |
| Matrix Metalloproteinase 2 | |
| Peptides | |
| Polymers |
Source PubMed
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32283007 | Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. | ACS Nano | 2020 | https://conductscience.org/library/papers/32283007 | PubMed |
| 2 | 31413527 | Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/31413527 | PubMed |
| 3 | 34174350 | Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. | J Control Release | 2021 | https://conductscience.org/library/papers/34174350 | PubMed |
| 4 | 32553783 | Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. | Adv Drug Deliv Rev | 2020 | https://conductscience.org/library/papers/32553783 | PubMed |
| 5 | 34580473 | Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34580473 | PubMed |
| 6 | 31427820 | Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31427820 | PubMed |
| 7 | 30886395 | Immunotherapy in colorectal cancer: rationale, challenges and potential. | Nat Rev Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/30886395 | PubMed |
| 8 | 34105277 | Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation. | Adv Sci (Weinh) | 2021 | https://conductscience.org/library/papers/34105277 | PubMed |
| 9 | 28163220 | Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. | Int J Pharm | 2017 | https://conductscience.org/library/papers/28163220 | PubMed |
| 10 | 31810556 | Antigen processing and presentation. | Int Rev Cell Mol Biol | 2019 | https://conductscience.org/library/papers/31810556 | PubMed |
| 11 | 32760014 | Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/32760014 | PubMed |
| 12 | 33995609 | Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy. | Asian J Pharm Sci | 2021 | https://conductscience.org/library/papers/33995609 | PubMed |
| 13 | 32209603 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32209603 | PubMed |
| 14 | 32194854 | Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. | Theranostics | 2020 | https://conductscience.org/library/papers/32194854 | PubMed |
| 15 | 28555136 | Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. | Front Immunol | 2017 | https://conductscience.org/library/papers/28555136 | PubMed |
| 16 | 26176173 | Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. | Hum Gene Ther | 2015 | https://conductscience.org/library/papers/26176173 | PubMed |
| 17 | 30498202 | Non-invasive delivery strategies for biologics. | Nat Rev Drug Discov | 2019 | https://conductscience.org/library/papers/30498202 | PubMed |
| 18 | 33997867 | A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer. | J Mater Chem B | 2021 | https://conductscience.org/library/papers/33997867 | PubMed |
| 19 | 22658128 | Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658128 | PubMed |
| 20 | 33098912 | Dendronized polymer conjugates with amplified immunogenic cell death for oncolytic immunotherapy. | J Control Release | 2021 | https://conductscience.org/library/papers/33098912 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42609883 | Polymeric Nanoparticles for Precision Tumor Immunotherapy: Rational Design Strategies and Spatiotemporal Immune Activation. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42609883 | PubMed |
| 42257206 | Harnessing Self-Assembling Peptides on γδ T Cells to Enhance Anti-Tumor Immunity. | Polym Sci Technol | 2026 | https://conductscience.org/library/papers/42257206 | PubMed |
| 42118213 | Mechanism-Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42118213 | PubMed |
| 41672596 | Immunobiological mechanisms of action of oncolytic peptides. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41672596 | PubMed |
| 40959869 | A Serum-Stable Antimicrobial Peptide-Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40959869 | PubMed |
| 40591134 | Bibliometric analysis of programmed cell death and immunogenic cell death in hepatocellular carcinoma immunotherapy: global trends and future directions. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40591134 | PubMed |
| 40336045 | Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40336045 | PubMed |
| 39882247 | DAMPs prognostic signature predicts tumor immunotherapy, and identifies immunosuppressive mechanism of pannexin 1 channels in pancreatic ductal adenocarcinoma. | Front Immunol | 2024 | https://conductscience.org/library/papers/39882247 | PubMed |
| 39653795 | Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression. | Oncogene | 2025 | https://conductscience.org/library/papers/39653795 | PubMed |
| 39309492 | Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/39309492 | PubMed |
| 37284456 | Nanoblock-mediated selective oncolytic polypeptide therapy for triple-negative breast cancer. | Theranostics | 2023 | https://conductscience.org/library/papers/37284456 | PubMed |
| 36986636 | Smart Polymeric Nanoparticles in Cancer Immunotherapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36986636 | PubMed |
| 36765028 | A biomimetic nanoplatform for customized photothermal therapy of HNSCC evaluated on patient-derived xenograft models. | Int J Oral Sci | 2023 | https://conductscience.org/library/papers/36765028 | PubMed |
| 36278104 | Functionalized Peptide-Based Nanoparticles for Targeted Cancer Nanotherapeutics: A State-of-the-Art Review. | ACS Omega | 2022 | https://conductscience.org/library/papers/36278104 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CALR | 811 | PubTator's text mining | https://conductscience.org/library/genes/811 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| HMGB1 | 3146 | PubTator's text mining | https://conductscience.org/library/genes/3146 | NCBI Gene |
| ITGAX | 3687 | PubTator's text mining | https://conductscience.org/library/genes/3687 | NCBI Gene |
| MMP2 | 4313 | PubTator's text mining | https://conductscience.org/library/genes/4313 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35547769
GET https://conductscience.org/api/papers/v1/35547769/references?page=2